BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $97 from $86 and keeps a Buy rating on the shares after having hosted fireside chats with management teams at the firm’s CNS Therapeutics Conference.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Promising Growth Driven by Key Product Launches and Strategic Partnerships
- Ionis Pharmaceuticals gets Breakthrough Therapy designation for zilganersen
- Ionis Pharmaceuticals granted Breakthrough Therapy designation for olezarsen
- Arrowhead price target raised to $48 from $27 at Goldman Sachs
- Ionis Pharmaceuticals Completes $770M Convertible Notes Offering